Shares of Kymera Therapeutics (NASDAQ:KYMR) spiked on Tuesday after the developer of oral protein degraders outlined its 2025 ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Kymera Therapeutics (KYMR) announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology ...

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women ...

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a ...

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...